Mark D Gershman
Overview
Explore the profile of Mark D Gershman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walker A, Gershman M, Rao S, LaRocque R, Ryan E
Am J Trop Med Hyg
. 2021 Feb;
104(3):1079-1084.
PMID: 33534766
In 2016, Sanofi Pasteur (S-P) experienced a manufacturing disruption of YF-Vax, the only U.S.-licensed yellow fever vaccine depleting the U.S. supply by mid-2017. Sanofi Pasteur received approval to import Stamaril,...
2.
Gershman M, Sotir M
MMWR Morb Mortal Wkly Rep
. 2017 Jul;
66(29):780.
PMID: 28749924
Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the United States, has announced that their stock of YF-VAX is totally depleted as of July 24,...
3.
Gershman M, Angelo K, Ritchey J, Greenberg D, Muhammad R, Brunette G, et al.
MMWR Morb Mortal Wkly Rep
. 2017 May;
66(17):457-459.
PMID: 28472025
Recent manufacturing problems resulted in a shortage of the only U.S.-licensed yellow fever vaccine. This shortage is expected to lead to a complete depletion of yellow fever vaccine available for...
4.
Deshpande B, Rao S, Jentes E, Hills S, Fischer M, Gershman M, et al.
Am J Trop Med Hyg
. 2014 Jul;
91(4):694-698.
PMID: 25070999
Few data regarding the use of Japanese encephalitis (JE) vaccine in clinical practice are available. We identified 711 travelers at higher risk and 7,578 travelers at lower risk for JE...
5.
Gaines J, Sotir M, Cunningham T, Harvey K, Lee C, Stoney R, et al.
JAMA Intern Med
. 2014 Jun;
174(8):1383-90.
PMID: 24887552
Importance: Travelers from around the globe will attend the 2014 Fédération Internationale de Football Association (FIFA) World Cup and the 2016 Olympic and Paralympic Games in Brazil. Travelers to these...
6.
7.
Jentes E, Han P, Gershman M, Rao S, LaRocque R, Staples J, et al.
Am J Trop Med Hyg
. 2013 Mar;
88(5):954-961.
PMID: 23458961
Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk...
8.
Gershman M, Staples J, Bentsi-Enchill A, Breugelmans J, Brito G, Camacho L, et al.
Vaccine
. 2012 May;
30(33):5038-58.
PMID: 22561144
No abstract available.
9.
Jentes E, Poumerol G, Gershman M, Hill D, Lemarchand J, Lewis R, et al.
Lancet Infect Dis
. 2011 Jul;
11(8):622-32.
PMID: 21798462
The changing epidemiology of yellow fever and continued reports of rare but serious adverse events associated with yellow fever vaccine have drawn attention to the need to revisit criteria for...
10.
Gershman M, Kennedy D, Noble-Wang J, Kim C, Gullion J, Kacica M, et al.
Clin Infect Dis
. 2008 Oct;
47(11):1372-9.
PMID: 18937575
Background: Pharmaceutical compounding, the manipulation of ingredients to create a customized medication, is a widespread practice. In January 2005, the Centers for Disease Control and Prevention was notified of 4...